Nektar Therapeutics, a San Francisco-based biopharmaceutical company with 137 employees, focuses on developing immunotherapy medicines for oncology and immunology, including NKTR-255 and Rezpegaldesleukin. Its pipeline targets immune response pathways to address cancer and autoimmune conditions.
Jonathan Zalevsky sold 51,115 shares of NKTR on 19 December at $0.94 per share, worth a total of $48K. They now own 326,904 NKTR shares, or a 14% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
